Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Somavert (pegvisomant for injection)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2012

 

Summary View

 

PRECAUTIONS

  • Patients should be instructed in the technique and importance of proper disposal of materials used for the administration of Somavert (e.g., needles and syringes, medical waste, vial). Patients should be cautioned against reuse of needles.

ADVERSE REACTIONS

Post-Marketing Experience
  • Systemic hypersensitivity reactions including anaphylactic/anaphylactoid reactions, laryngospasm, angioedema, generalized skin reactions (rash, erythema, pruritus, urticaria) have been reported in post-marketing use. Some patients required hospitalization. Symptoms did not re-occur in all patients after re-challenge
-
-